Compile Data Set for Download or QSAR
Report error Found 1940 Enz. Inhib. hit(s) with Target = 'eIF-2-alpha kinase GCN2'
TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM614966(US20230271939, Example 4)
Affinity DataKi:  0.300nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM614995(US20230271939, Example 33)
Affinity DataKi:  0.300nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM614999(US20230271939, Example 37)
Affinity DataKi:  0.300nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM615005(US20230271939, Comp Ex 4 | WO2018030466, Example 5)
Affinity DataKi:  0.5nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM614965(US20230271939, Example 3 | US20230271939, Compound...)
Affinity DataKi:  0.600nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM614985(US20230271939, Example 23)
Affinity DataKi:  0.600nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM614965(US20230271939, Example 3 | US20230271939, Compound...)
Affinity DataKi:  0.600nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM614973(US20230271939, Example 11)
Affinity DataKi:  0.700nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM614994(US20230271939, Example 32)
Affinity DataKi:  0.700nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM615000(US20230271939, Example 38)
Affinity DataKi:  0.800nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM614968(US20230271939, Example 6)
Affinity DataKi:  0.800nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM614972(US20230271939, Example 10)
Affinity DataKi:  0.900nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM614979(US20230271939, Example 17)
Affinity DataKi:  0.900nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM614966(US20230271939, Example 4)
Affinity DataKi:  0.900nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM615001(US20230271939, Comp Ex 1)
Affinity DataKi:  0.900nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM615002(US20230271939, Comp Ex 2 | WO2018030466, Example 1...)
Affinity DataKi:  1.10nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM614965(US20230271939, Example 3 | US20230271939, Compound...)
Affinity DataKi:  1.10nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM614965(US20230271939, Example 3 | US20230271939, Compound...)
Affinity DataKi:  1.10nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM614973(US20230271939, Example 11)
Affinity DataKi:  1.10nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM765942(2,5-dichloro-N- (3-(2-(((1R,4R)-4- (dimethylamino)...)
Affinity DataIC50: 1.11nMAssay Description:TBDMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM614964(US20230271939, Example 2)
Affinity DataKi:  1.20nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM614995(US20230271939, Example 33)
Affinity DataKi:  1.30nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM784327(US20250340530, Example 8)
Affinity DataKi:  1.40nMAssay Description:Recombinant Cat D was expressed in CHO cells. The assay buffer for CathepsinD is 0.05 M citrate pH 3.5, 10% DMSO final, 5 mM CHAPS. The Cat D enzyme ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
2/25/2026
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM784338(US20250340530, Example 19)
Affinity DataKi:  1.5nMAssay Description:Recombinant Cat D was expressed in CHO cells. The assay buffer for CathepsinD is 0.05 M citrate pH 3.5, 10% DMSO final, 5 mM CHAPS. The Cat D enzyme ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
2/25/2026
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM614993(US20230271939, Example 31)
Affinity DataKi:  1.5nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM614984(US20230271939, Example 22)
Affinity DataKi:  1.5nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM784326(US20250340530, Example 7)
Affinity DataKi:  1.60nMAssay Description:Recombinant Cat D was expressed in CHO cells. The assay buffer for CathepsinD is 0.05 M citrate pH 3.5, 10% DMSO final, 5 mM CHAPS. The Cat D enzyme ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
2/25/2026
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM614963(US20230271939, Example 1 | US20230271939, Compound...)
Affinity DataKi:  1.60nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM614963(US20230271939, Example 1 | US20230271939, Compound...)
Affinity DataKi:  1.60nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM784331(US20250340530, Example 12)
Affinity DataKi:  1.60nMAssay Description:Recombinant Cat D was expressed in CHO cells. The assay buffer for CathepsinD is 0.05 M citrate pH 3.5, 10% DMSO final, 5 mM CHAPS. The Cat D enzyme ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
2/25/2026
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM614969(US20230271939, Example 7)
Affinity DataKi:  1.60nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM765946(N-(3-(2- (((1R,4R)-4- aminocyclohexyl) amino)quina...)
Affinity DataIC50: 1.64nMAssay Description:TBDMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM614978(US20230271939, Example 16)
Affinity DataKi:  1.70nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM614971(US20230271939, Example 9)
Affinity DataKi:  1.70nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM784320(US20250340530, Example 1)
Affinity DataKi:  1.70nMAssay Description:Recombinant Cat D was expressed in CHO cells. The assay buffer for CathepsinD is 0.05 M citrate pH 3.5, 10% DMSO final, 5 mM CHAPS. The Cat D enzyme ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
2/25/2026
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM614987(US20230271939, Example 25)
Affinity DataKi:  1.70nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM615005(US20230271939, Comp Ex 4 | WO2018030466, Example 5)
Affinity DataKi:  1.80nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM784329(US20250340530, Example 10)
Affinity DataKi:  1.90nMAssay Description:Recombinant Cat D was expressed in CHO cells. The assay buffer for CathepsinD is 0.05 M citrate pH 3.5, 10% DMSO final, 5 mM CHAPS. The Cat D enzyme ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
2/25/2026
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM784324(US20250340530, Example 5)
Affinity DataKi:  1.90nMAssay Description:Recombinant Cat D was expressed in CHO cells. The assay buffer for CathepsinD is 0.05 M citrate pH 3.5, 10% DMSO final, 5 mM CHAPS. The Cat D enzyme ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
2/25/2026
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM784351(US20250340530, Comparative Example 1)
Affinity DataKi:  1.90nMAssay Description:Recombinant Cat D was expressed in CHO cells. The assay buffer for CathepsinD is 0.05 M citrate pH 3.5, 10% DMSO final, 5 mM CHAPS. The Cat D enzyme ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
2/25/2026
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM784330(US20250340530, Example 11)
Affinity DataKi:  1.90nMAssay Description:Recombinant Cat D was expressed in CHO cells. The assay buffer for CathepsinD is 0.05 M citrate pH 3.5, 10% DMSO final, 5 mM CHAPS. The Cat D enzyme ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
2/25/2026
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM615001(US20230271939, Comp Ex 1)
Affinity DataKi:  1.90nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM50591075(CHEMBL5200118)
Affinity DataIC50: 2nMAssay Description:Inhibition of GCN2 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM784333(US20250340530, Example 14)
Affinity DataKi:  2nMAssay Description:Recombinant Cat D was expressed in CHO cells. The assay buffer for CathepsinD is 0.05 M citrate pH 3.5, 10% DMSO final, 5 mM CHAPS. The Cat D enzyme ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
2/25/2026
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM614968(US20230271939, Example 6)
Affinity DataKi:  2.10nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/15/2023
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM765924((1R,3R)-3-((6-(3- ((2,5-dichloro-3- (hydroxymethyl...)
Affinity DataIC50: 2.12nMAssay Description:TBDMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/3/2025
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM784323(US20250340530, Example 4)
Affinity DataKi:  2.20nMAssay Description:Recombinant Cat D was expressed in CHO cells. The assay buffer for CathepsinD is 0.05 M citrate pH 3.5, 10% DMSO final, 5 mM CHAPS. The Cat D enzyme ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
2/25/2026
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM784321(US20250340530, Example 2)
Affinity DataKi:  2.20nMAssay Description:Recombinant Cat D was expressed in CHO cells. The assay buffer for CathepsinD is 0.05 M citrate pH 3.5, 10% DMSO final, 5 mM CHAPS. The Cat D enzyme ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
2/25/2026
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM734458(US20250129068, Example 17)
Affinity DataKi:  2.28nMAssay Description:The inhibitory activity of the Example compounds towards GCN2 enzyme was measured according to the description below, using a LanthaScreen TR-FRET (T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/25/2025
Entry Details
US Patent

TargeteIF-2-alpha kinase GCN2(Human)
Ip2Ipo Innovations

US Patent
LigandPNGBDBM784342(US20250340530, Example 23)
Affinity DataKi:  2.30nMAssay Description:Recombinant Cat D was expressed in CHO cells. The assay buffer for CathepsinD is 0.05 M citrate pH 3.5, 10% DMSO final, 5 mM CHAPS. The Cat D enzyme ...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
2/25/2026
Entry Details
US Patent

Displayed 1 to 50 (of 1940 total ) | Next | Last >>
Jump to: